Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database
- PMID: 33071196
- DOI: 10.1016/j.carrev.2020.08.038
Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database
Abstract
Background/purpose: Coronary artery calcification is a marker of advanced atherosclerosis and a predictor of adverse clinical outcomes. Rotational atherectomy (RA) can effectively modify calcified lesions, optimizing procedural outcomes. We interrogated the most commonly reported adverse events involving rotational atherectomy systems (Rotablator and Rotapro) by analyzing post-marketing surveillance data from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database.
Methods/materials: We queried MAUDE from September 1, 2016, through December 31, 2019. After excluding duplicate reports, we included 363 reports for Rotablator and 63 reports for Rotapro in the final analysis.
Results: Percentages represent the proportion of total submitted MAUDE reports. The most commonly reported complications for Rotablator and Rotapro included dissection (2.7% and 6.3%, respectively) and perforation (4.1% and 19%, respectively). The most commonly reported device-related issues included detachment or structural damage, or both, for Rotablator (39.1%) and entrapment of the device component for Rotapro (47.6%). The most commonly damaged device component was the Rotawire, whereas the most commonly entrapped device component was the Rotaburr for both device configurations. Rotablator and Rotapro device-related complications were most commonly reported for the left anterior descending artery.
Conclusion: An analysis of the MAUDE database demonstrates that in real-world practice, RA devices are associated with important complications. Ongoing surveillance of safety profiles, patient outcomes, and failure modes of RA devices is warranted. Our analysis provides important insights into the mechanisms of failure of RA devices and associated complications but cannot verify causality.
Keywords: Atherectomy; Calcified stenosis; Rotational atherectomy.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest RW –Advisory Board: Amgen, Boston Scientific, Cardioset, Cardiovascular Systems Inc., Medtronic, Philips, Pi-Cardia Ltd.; Consultant: Amgen, Biotronik, Boston Scientific, Cardioset, Cardiovascular Systems Inc., Medtronic, Philips, Pi-Cardia Ltd.; Grant Support: AstraZeneca, Biotronik, Boston Scientific, Chiesi; Speakers Bureau: AstraZeneca, Chiesi; Investor: MedAlliance. TR – Proctor and Consultant: Medtronic, Edwards Lifesciences; Advisory Board: Medtronic; Equity interest: Transmural Systems. All other authors: None.
Similar articles
-
Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study.Cardiol J. 2023;30(4):526-533. doi: 10.5603/CJ.a2021.0128. Epub 2021 Oct 21. Cardiol J. 2023. PMID: 34671968 Free PMC article.
-
Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for Patient- and Circuit-Related Adverse Events Involving Extracorporeal Membrane Oxygenation.Cardiovasc Revasc Med. 2020 Feb;21(2):230-234. doi: 10.1016/j.carrev.2019.11.011. Epub 2019 Nov 20. Cardiovasc Revasc Med. 2020. PMID: 31767523
-
Adverse events and modes of failure related to the FilterWire EZ Embolic Protection System: Lessons learned from an analytic review of the FDA MAUDE database.Catheter Cardiovasc Interv. 2019 Jul 1;94(1):157-164. doi: 10.1002/ccd.28297. Epub 2019 Apr 15. Catheter Cardiovasc Interv. 2019. PMID: 30985082
-
Orbital atherectomy versus rotational atherectomy: A systematic review and meta-analysis.Int J Cardiol. 2020 Mar 15;303:16-21. doi: 10.1016/j.ijcard.2019.12.037. Epub 2019 Dec 17. Int J Cardiol. 2020. PMID: 31898984
-
Guidewire fracture during orbital atherectomy for peripheral artery disease: Insights from the Manufacturer and User Facility Device Experience database.Catheter Cardiovasc Interv. 2019 Feb 1;93(2):330-334. doi: 10.1002/ccd.27933. Epub 2018 Nov 1. Catheter Cardiovasc Interv. 2019. PMID: 30387234
Cited by
-
Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data.J Patient Saf. 2024 Aug 1;20(5):e45-e58. doi: 10.1097/PTS.0000000000001220. Epub 2024 Mar 12. J Patient Saf. 2024. PMID: 38470959 Free PMC article.
-
Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study.Cardiol J. 2023;30(4):526-533. doi: 10.5603/CJ.a2021.0128. Epub 2021 Oct 21. Cardiol J. 2023. PMID: 34671968 Free PMC article.
-
Insights From the FDA's MAUDE Database Regarding the Real-World Safety of Jetstream Atherectomy for Peripheral Arterial Disease.J Endovasc Ther. 2025 Aug;32(4):1067-1074. doi: 10.1177/15266028231202718. Epub 2023 Sep 26. J Endovasc Ther. 2025. PMID: 37750495 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical